Balancing Long-Term Risks of Ischemic and Bleeding Complications after Percutaneous Coronary Intervention with Drug-Eluting Stents

American Journal of Cardiology

Volumn 116, Issue 5, 2015, Pages 686-693

  Matteau, Alexis ^a   Yeh, Robert W ^b   Camenzind, Edoardo ^c   Steg, P Gabriel ^d,e,f   Wijns, William ^g   Mills, Joseph ^h   Gershlick, Anthony ^i,j   De Belder, Mark ^k   Ducrocq, Gregory ^d,e,f   Mauri, Laura ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^g OLV HOSPITAL   (Belgium)

^h LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

^j GLENFIELD HOSPITAL   (United Kingdom)

^k JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR; SIROLIMUS ELUTING CORONARY STENT; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ELUTING STENT; EUROPE; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; POSTOPERATIVE HEMORRHAGE; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME FACTOR; TRENDS;

ANTITHROMBOCYTIC AGENT; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN; ZOTAROLIMUS;

AGED; BLOOD TRANSFUSION; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; PROGNOSIS; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TIME FACTORS;

EID: 84942826111     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.05.036     Document Type: Article

References (27)

1. E.L. Eisenstein, K.J. Anstrom, D.F. Kong, L.K. Shaw, R.H. Tuttle, D.B. Mark, J.M. Kramer, R.A. Harrington, D.B. Matchar, D.E. Kandzari, E.D. Peterson, K.A. Schulman, and R.M. Califf Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 297 2007 159 168
2. G. Giustino, U. Baber, S. Sartori, R. Mehran, I. Mastoris, A.S. Kini, S.K. Sharma, S.J. Pocock, and G.D. Dangas Duration of dual antiplatelet therapy following drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials J Am Coll Cardiol 65 2015 1298 1310
3. L. Mauri, D.J. Kereiakes, R.W. Yeh, P. Driscoll-Shempp, D.E. Cutlip, P.G. Steg, S.L. Normand, E. Braunwald, S.D. Wiviott, D.J. Cohen, D.R. Holmes Jr., M.W. Krucoff, J. Hermiller, H.L. Dauerman, D.I. Simon, D.E. Kandzari, K.N. Garratt, D.P. Lee, T.K. Pow, P. Ver Lee, M.J. Rinaldi, and J.M. Massaro Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
4. S. Schulz-Schupke, R.A. Byrne, J.M. Ten Berg, F.J. Neumann, Y. Han, T. Adriaenssens, R. Tolg, M. Seyfarth, M. Maeng, B. Zrenner, C. Jacobshagen, H. Mudra, E. von Hodenberg, J. Wohrle, D.J. Angiolillo, B. von Merzljak, N. Rifatov, S. Kufner, T. Morath, A. Feuchtenberger, T. Ibrahim, P.W. Janssen, C. Valina, Y. Li, W. Desmet, M. Abdel-Wahab, K. Tiroch, C. Hengstenberg, I. Bernlochner, M. Fischer, H. Schunkert, K.L. Laugwitz, A. Schomig, J. Mehilli, and A. Kastrati ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting Eur Heart J 36 2015 1252 1263
5. S.J. Park, D.W. Park, Y.H. Kim, S.J. Kang, S.W. Lee, C.W. Lee, K.H. Han, S.W. Park, S.C. Yun, S.G. Lee, S.W. Rha, I.W. Seong, M.H. Jeong, S.H. Hur, N.H. Lee, J. Yoon, J.Y. Yang, B.K. Lee, Y.J. Choi, W.S. Chung, D.S. Lim, S.S. Cheong, K.S. Kim, J.K. Chae, D.Y. Nah, D.S. Jeon, K.B. Seung, J.S. Jang, H.S. Park, and K. Lee Duration of dual antiplatelet therapy after implantation of drug-eluting stents N Engl J Med 362 2010 1374 1382
6. H.C. Gwon, J.Y. Hahn, K.W. Park, Y.B. Song, I.H. Chae, D.S. Lim, K.R. Han, J.H. Choi, S.H. Choi, H.J. Kang, B.K. Koo, T. Ahn, J.H. Yoon, M.H. Jeong, T.J. Hong, W.Y. Chung, Y.J. Choi, S.H. Hur, H.M. Kwon, D.W. Jeon, B.O. Kim, S.H. Park, N.H. Lee, H.K. Jeon, Y. Jang, and H.S. Kim Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus versus Cypher to Reduce Late Loss after Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
7. M. Valgimigli, G. Campo, M. Monti, P. Vranckx, G. Percoco, C. Tumscitz, F. Castriota, F. Colombo, M. Tebaldi, G. Fuca, M. Kubbajeh, E. Cangiano, M. Minarelli, A. Scalone, C. Cavazza, A. Frangione, M. Borghesi, J. Marchesini, G. Parrinello, and R. Ferrari Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
8. F. Feres, R.A. Costa, A. Abizaid, M.B. Leon, J.A. Marin-Neto, R.V. Botelho, S.B. King III, M. Negoita, M. Liu, J.E. de Paula, J.A. Mangione, G.X. Meireles, H.J. Castello Jr., E.L. Nicolela Jr., M.A. Perin, F.S. Devito, A. Labrunie, D. Salvadori Jr., M. Gusmao, R. Staico, J.R. Costa Jr., J.P. de Castro, A.S. Abizaid, and D.L. Bhatt Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
9. J.P. Collet, J. Silvain, O. Barthelemy, G. Range, G. Cayla, E. Van Belle, T. Cuisset, S. Elhadad, F. Schiele, N. Lhoest, P. Ohlmann, D. Carrie, H. Rousseau, P. Aubry, J. Monsegu, P. Sabouret, S.A. O'Connor, J. Abtan, M. Kerneis, C. Saint-Etienne, F. Beygui, E. Vicaut, and G. Montalescot Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Lancet 384 2014 1577 1585
10. P. Garg, B.Z. Galper, D.J. Cohen, R.W. Yeh, and L. Mauri Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents Am Heart J 169 2015 222 233.e5
11. E. Camenzind, W. Wijns, L. Mauri, E. Boersma, K. Parikh, V. Kurowski, R. Gao, C. Bode, J.P. Greenwood, A. Gershlick, W. O'Neill, P.W. Serruys, B. Jorissen, P.G. Steg PROTECT Steering Committee and Investigators Rationale and design of the Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation Am Heart J 158 2009 902 909.e5
12. E. Camenzind, W. Wijns, L. Mauri, V. Kurowski, K. Parikh, R. Gao, C. Bode, J.P. Greenwood, E. Boersma, P. Vranckx, E. McFadden, P.W. Serruys, W.W. O'Neil, B. Jorissen, F. Van Leeuwen, and P.G. Steg Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial Lancet 380 2012 1396 1405
13. K. Thygesen, J.S. Alpert, and H.D. White Universal definition of myocardial infarction Circulation 116 2007 2634 2653
14. E.W. Steyerberg, F.E. Harrell Jr., G.J. Borsboom, M.J. Eijkemans, Y. Vergouwe, and J.D. Habbema Internal validation of predictive models: efficiency of some procedures for logistic regression analysis J Clin Epidemiol 54 2001 774 781
15. E.M. Antman, M. Cohen, P.J. Bernink, C.H. McCabe, T. Horacek, G. Papuchis, B. Mautner, R. Corbalan, D. Radley, and E. Braunwald The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making JAMA 284 2000 835 842
16. K.A. Eagle, M.J. Lim, O.H. Dabbous, K.S. Pieper, R.J. Goldberg, F. Van de Werf, S.G. Goodman, C.B. Granger, P.G. Steg, J.M. Gore, A. Budaj, A. Avezum, M.D. Flather, and K.A. Fox A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733
17. G. Sianos, M.A. Morel, A.P. Kappetein, M.C. Morice, A. Colombo, K. Dawkins, M. van den Brand, N. Van Dyck, M.E. Russell, F. Mohr, and P.W. Serruys The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease EuroIntervention 1 2005 219 227
18. S.L. Chen, J.P. Chen, G. Mintz, B. Xu, J. Kan, F. Ye, J. Zhang, X. Sun, Y. Xu, Q. Jiang, A. Zhang, and G.W. Stone Comparison between the NERS (New Risk Stratification) score and the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score in outcome prediction for unprotected left main stenting JACC Cardiovas Interv 3 2010 632 641
19. S. Garg, G. Sarno, H.M. Garcia-Garcia, C. Girasis, J. Wykrzykowska, K.D. Dawkins, and P.W. Serruys A new tool for the risk stratification of patients with complex coronary artery disease: the clinical SYNTAX score Circ Cardiovasc Interv 3 2010 317 326
20. V. Farooq, Y. Vergouwe, L. Raber, P. Vranckx, H. Garcia-Garcia, R. Diletti, A.P. Kappetein, M.A. Morel, T. de Vries, M. Swart, M. Valgimigli, K.D. Dawkins, S. Windecker, E.W. Steyerberg, and P.W. Serruys Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the logistic clinical SYNTAX score Eur Heart J 33 2012 3098 3104
21. M. Ranucci, S. Castelvecchio, L. Menicanti, A. Frigiola, and G. Pelissero Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony Circulation 119 2009 3053 3061
22. J. Iqbal, Y. Vergouwe, C.V. Bourantas, D.V. Klaveren, Y.J. Zhang, C.M. Campos, H.M. Garcia-Garcia, M.A. Morel, M. Valgimigli, S. Windecker, E.W. Steyerberg, and P.W. Serruys Predicting 3-year mortality after percutaneous coronary intervention: updated logistic clinical SYNTAX score based on patient-level data from 7 contemporary stent trials JACC Cardiovasc Interv 7 2014 464 470
23. C. Wu, F.T. Camacho, S.B. King III, G. Walford, D.R. Holmes Jr., N.J. Stamato, P.B. Berger, S. Sharma, J.P. Curtis, F.J. Venditti, A.K. Jacobs, and E.L. Hannan Risk stratification for long-term mortality after percutaneous coronary intervention Circ Cardiovasc Interv 7 2014 80 87
24. E. Camenzind, E. Boersma, W. Wijns, L. Mauri, T. Rademaker-Havinga, F.F. Ordoubadi, M.J. Suttorp, M.A. Kurdi, and P.G. Steg Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type Eur Heart J 35 2014 1932 1948
25. D.L. Bhatt, M.D. Flather, W. Hacke, P.B. Berger, H.R. Black, W.E. Boden, P. Cacoub, E.A. Cohen, M.A. Creager, J.D. Easton, C.W. Hamm, G.J. Hankey, S.C. Johnston, K.H. Mak, J.L. Mas, G. Montalescot, T.A. Pearson, P.G. Steg, S.R. Steinhubl, M.A. Weber, L. Fabry-Ribaudo, T. Hu, E.J. Topol, and K.A. Fox Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial J Am Coll Cardiol 49 2007 1982 1988
26. G.D. Dangas, B.E. Claessen, R. Mehran, K. Xu, M. Fahy, H. Parise, J.P. Henriques, E.M. Ohman, H.D. White, and G.W. Stone Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes JACC Cardiovasc Interv 5 2012 1097 1105
27. R. Mehran, S. Pocock, E. Nikolsky, G.D. Dangas, T. Clayton, B.E. Claessen, A. Caixeta, F. Feit, S.V. Manoukian, H. White, M. Bertrand, E.M. Ohman, H. Parise, A.J. Lansky, A.M. Lincoff, and G.W. Stone Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials JACC Cardiovasc Interv 4 2011 654 664